Wednesday, March 05, 2025 | 01:27 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

<b>Bhupesh Bhandari:</b> Trump cloud on pharma's cash cow

Indian pharmaceutical companies say any crackdown on them will not be prudent

Image
Premium

Bhupesh Bhandari
The Nifty Pharma index has fallen 11.52 per cent in the last six months. All the heavyweights of the industry – Sun, Wockhardt, Lupin, Aurobindo – have shed value as investors fear the United States may restrict the import of inexpensive medicine.

The US is where these companies make money. India, under stringent price controls, does not hold much attraction for them. Now, with President Donald Trump all out to promote “Make in America”, Indian pharmaceutical majors could be in for a rough ride, it is feared.

Pharmacies in the US are allowed to hand out generic versions of the prescribed medicine
Disclaimer: These are personal views of the writer. They do not necessarily reflect the opinion of www.business-standard.com or the Business Standard newspaper

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in